Webinar: An RNA-Based Assay Designed to Predict Patient Response to Angiogenic and Immune Targeted Therapies

The following topics will be covered in this webinar:

  • Current challenges with predictive biomarkers for anti-angiogenic and immune targeting therapies
  • The RNA-based Xerna TMETM Panel and its ability to identify the dominant biology of the tumor microenvironment.
  • Potential clinical and research applications of the Xerna TME Panel designed support multiple oncology therapeutics, particularly immune checkpoint inhibitors and anti-angiogenic agents, across a variety of tumor types.
  • Future development of the Xerna TME Panel as an RUO and CDx assay.

Who should attend and benefits of attending:

  • Researchers and clinical investigators interested in learning about this novel, RNA-based precision medicine platform are encouraged to attend.
  • Participants will achieve a greater understanding of how the Xerna TME Panel was developed to understand the dominant biology of the tumor microenvironment and align to particular therapeutic modalities.

Featured Speaker

Mark Uhlik

Vice President, Head of Research and Biomarker Discovery

OncXerna Therapeutics

Mark is a seasoned leader in translational oncology and drug discovery/development with over 15 years of experience in the pharmaceutical industry. Mark earned his B.S. in Microbiology from Colorado State University and his Ph.D. in Microbiology and Immunology at Pennsylvania State University College of Medicine. He performed post-doctoral work at University of Colorado Health Sciences Center and at University of North Carolina School of Medicine. Mark has authored over 35 peer-reviewed publications in addition to book chapters and patents.

Date:  Wednesday, October 27, 2021
Time:  11am ET / 8am PT
Duration:  1 Hour

Register now for this webinar

© 2021 Questex LLC, All right reserved.

685 Third Avenue, 21st Floor New York, NY 10017

Reproduction in whole or part is prohibited.